The DOI matches its Crossref record.
Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease
Abstract
Nuclear receptors (NRs) are ligand-activated transcriptional regulators of several key metabolic processes including hepatic lipid and glucose metabolism, bile acid homeostasis, and energy expenditure as well as inflammation, fibrosis, and cellular proliferation in the liver. Dysregulation of these processes contributes to the pathogenesis and progression of nonalcoholic fatty liver disease (NAFLD). This places NRs at the forefront of novel therapeutic approaches for NAFLD. Some NRs are already pharmacologically targeted in metabolic disorders such as hyperlipidemia (peroxisomal proliferator-activated receptor α [PPARα], fibrates) and diabetes (PPARγ, glitazones) with potential applications for NAFLD. Other NRs with potential therapeutic implications are the vitamin D receptor (VDR) and xenobiotic sensors such as constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Further new perspectives include combined ligands for NR isoforms such as PPARα/δ ligands. Other novel key players represent the nuclear bile acid receptor farnesoid X receptor (FXR; targeted by synthetic FXR ligands such as obeticholic acid) and RAR-related orphan receptor gamma two (RORγt). In this review the authors provide an overview of the preclinical and clinical evidence of current and future treatment strategies targeting NRs in metabolism, inflammation, and fibrogenesis of NAFLD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FXR agonism has shown benefit in several preclinical models of NAFLD/NASH, inducing metabolic effects that reduce steatosis and inflammation (Figure 3) [250].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [250]
Citations
Cites
Still being checked.
Cited by
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847
Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
Arab, J. P., Karpen, S. J., Dawson, P. A., Arrese, M., & Trauner, M. (2017) · Hepatology · doi:10.1002/hep.28709 · Cited by 634
“Of note, changes in circulating BAs with potential benefit for NAFLD/NASH can be achieved through modulation of BA transporters or manipulation of GM.((11,28)) Existing data on targeting BA-related pathways for NAFLD treatment is summarized below.”
BackgroundInfluentialSelf-citationRecent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573
Self-citationNon-alcoholic fatty liver disease and dyslipidemia: An update
Katsiki, N., Mikhailidis, D. P., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.05.003 · Cited by 564
Metadata
- Authors
- Fuchs, C., Traussnigg, S., & Trauner, M.
- Affiliations
- Medical University of Vienna (AT)
- Corresponding author
- Trauner, Michael
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2016-02-12
- Volume
- 36
- Issue
- 01
- Pages
- 069-086
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W2286534347
- Cited by
- 100
- References
- 0
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 10 · 2023: 7 · 2022: 11 · 2021: 17 · 2020: 10 · 2019: 7 · 2018: 15 · 2017: 11 · 2016: 8
- FWCI
- 12.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Seminars in Liver Disease (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Universidad de Chile
- Pontificia Universidad Católica de Chile
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- nuclear receptors, non-alcoholic fatty liver disease, PPARα, PPARγ, vitamin D receptor, constitutive androstane receptor, pregnane X receptor, farnesoid X receptor, obeticholic acid, RORγt, hepatic lipid metabolism, hepatic glucose metabolism, bile acid homeostasis, liver inflammation, liver fibrosis
- MeSH terms
- Animals, Anti-Inflammatory Agents, Humans, Liver, Liver Cirrhosis, Signal Transduction, Treatment Outcome, Receptors, Cytoplasmic and Nuclear, Molecular Targeted Therapy, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease. https://app.cochat.ai/papers/10.1055/s-0036-1571296
- The paper
- Fuchs, C., Traussnigg, S., & Trauner, M. (2016). Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease. https://doi.org/10.1055/s-0036-1571296
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.